secwatch.observer — SEC 8-K summary
======================================

Issuer:     enGene Therapeutics Inc. (ENGN)
CIK:        0001980845
Form:       8-K
Filed at:   2024-02-14T23:59:59+00:00
Accession:  0001193125-24-035074
Event type: other_material
Sentiment:  neutral
Materiality: 0.80
Item codes: 1.01, 3.02, 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

enGene raises $200M via oversubscribed private placement; CEO Hanson to resign for family/health reasons
--------------------------------------------------------------------------------

- Sold 20M shares at $10.00 each (31% premium to Feb 13 close); gross proceeds $200M; expected close Feb 16.
- New and existing investors participated, including Adage, Blue Owl, Boxer, Cormorant, Deerfield, and Janus Henderson.
- Proceeds to fund EG-70 pivotal study for BCG-unresponsive NMIBC; cash runway extends into 2027.
- CEO Jason Hanson to resign upon successor appointment due to personal family/health reasons; Board initiated search.
- Hanson will serve as Senior Strategic Advisor for at least six months post-resignation at $25,000/month.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1980845/000119312524035074/0001193125-24-035074-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1980845/000119312524035074/d772510d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-035074

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer